ScreenerHero

LIMNLiminatus Pharma Inc. Class A Common Stock

NAS · US · Healthcare · Biotechnology · liminatuspharma.com
5.160USD+4519.52%Mkt Cap: 6.93M $P/E: —

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phas…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.93M $
Enterprise Value5.99M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.21M $
Revenue/Share—
Last Price5.160 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.47
EV/Revenue—
P/S—
P/B-37.53
EPS (TTM)-24.52
EPS (Forward)—
52W Range
0.095288% of range5.876
52W High5.876 USD
52W Low0.0952 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE103.99%
ROA-1990.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.96M $
CapEx (TTM)13.11K $
FCF Margin—
FCF Yield-144.36%
Net Debt-1.57M $
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity-0.15
Current Ratio1.12
Quick Ratio0.99
Book Value/Sh-0.0030 USD
Cash/Share0.0450 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateAug 21, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.34M
Float35.44M
Insiders33.75%
Institutions1.44%
Short Interest
Short Ratio0.1d
Short % Float7.83%
Short % Out.6.30%
Shares Short84.68K
Short (prev mo.)23.34K
Technical
SMA 505.862 (-12.0%)
SMA 20019.78 (-73.9%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)45.48M
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)63.0
MACD0.9632
MACD Signal0.4130
MACD Hist.+0.5502
BB Upper5.130 USD
BB Middle0.9624 USD
BB Lower-3.2052 USD
BB Width866.12%
ATR (14)1.243 USD
Vol Ratio (20d)0.00x